Active Filter(s):
Details:
The portfolio to be divested includes a variety of over-the-counter medicines and health products. TCHC’s strong regional brands include Alinamin, and Benza.
Lead Product(s): Fursultiamine
Therapeutic Area: Ophthalmology Product Name: Alinamin
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Blackstone Life Sciences
Deal Size: $2,300.0 million Upfront Cash: Undisclosed
Deal Type: Divestment August 24, 2020